These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 17970092)
1. Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Palwai NR; Zang XP; Harrison RG; Pento JT Anticancer Res; 2007; 27(5A):3435-9. PubMed ID: 17970092 [TBL] [Abstract][Full Text] [Related]
2. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Zang XP; Palwai NR; Lerner MR; Brackett DJ; Pento JT; Harrison RG Anticancer Res; 2006; 26(3A):1745-51. PubMed ID: 16827102 [TBL] [Abstract][Full Text] [Related]
3. Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Peron K; Jones TN; Gauthier SA; Nguyen TN; Zang XP; Barriere M; Prévéraud D; Soliman CE; Harrison RG; Pento JT Cancer Chemother Pharmacol; 2003 Oct; 52(4):270-6. PubMed ID: 12827296 [TBL] [Abstract][Full Text] [Related]
4. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Palwai NR; Zang XP; Harrison RG; Benbrook D; Pento JT Pharmacology; 2009; 84(5):271-5. PubMed ID: 19797936 [TBL] [Abstract][Full Text] [Related]
5. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143 [TBL] [Abstract][Full Text] [Related]
6. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Van Rite BD; Lazrak YA; Pagnon ML; Palwai NR; Neves LF; McFetridge PS; Harrison RG Cancer Lett; 2011 Feb; 301(2):177-84. PubMed ID: 21194833 [TBL] [Abstract][Full Text] [Related]
7. Anticancer efficacy of methioninase in vivo. Tan Y; Xu M; Guo H; Sun X; Kubota T; Hoffman RM Anticancer Res; 1996; 16(6C):3931-6. PubMed ID: 9042315 [TBL] [Abstract][Full Text] [Related]
8. Gene cloning and characterization of Pseudomonas putida L-methionine-alpha-deamino-gamma-mercaptomethane-lyase. Hori H; Takabayashi K; Orvis L; Carson DA; Nobori T Cancer Res; 1996 May; 56(9):2116-22. PubMed ID: 8616859 [TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751 [TBL] [Abstract][Full Text] [Related]
10. Broad selective efficacy of rMETase and PEG-rMETase on cancer cells in vitro. Tan Y; Xu M; Hoffman RM Anticancer Res; 2010 Mar; 30(3):793-8. PubMed ID: 20392998 [TBL] [Abstract][Full Text] [Related]
11. Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase. Guillen KP; Kurkjian C; Harrison RG J Biomed Sci; 2014 Jul; 21(1):65. PubMed ID: 25047949 [TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304 [TBL] [Abstract][Full Text] [Related]
14. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Huang YW; Wang LS; Dowd MK; Wan PJ; Lin YC Anticancer Res; 2009 Jun; 29(6):2179-88. PubMed ID: 19528479 [TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301 [TBL] [Abstract][Full Text] [Related]
16. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Massoner P; Colleselli D; Matscheski A; Pircher H; Geley S; Jansen Dürr P; Klocker H Endocr Relat Cancer; 2009 Sep; 16(3):795-808. PubMed ID: 19509068 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL; Lin JK Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333 [TBL] [Abstract][Full Text] [Related]
18. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Makovitzki A; Fink A; Shai Y Cancer Res; 2009 Apr; 69(8):3458-63. PubMed ID: 19351852 [TBL] [Abstract][Full Text] [Related]
19. Depletion of serum methionine by methioninase in mice. Lishko VK; Lishko OV; Hoffman RM Anticancer Res; 1993; 13(5A):1465-8. PubMed ID: 8239522 [TBL] [Abstract][Full Text] [Related]